open access

Vol 10, No 2 (2007)
Clinical nuclear medicine
Published online: 2007-05-23
Submitted: 2012-01-23
Get Citation

Radioimmunotherapy in follicular lymphomas, a retrospective analysis of the Polish Lymphoma Research Group’s (PLRG) experience

Wojciech Jurczak, Alicja Hubalewska-Dydejczyk, Agnieszka Giza, Anna Sowa-Staszczak, Tomasz Wróbel, Grzegorz Mazur, Piotr Boguradzki, Wanda Knopińska-Posłuszny, Bohdan Huszno, Aleksander B. Skotnicki
Nucl. Med. Rev 2007;10(2):91-97.

open access

Vol 10, No 2 (2007)
Clinical nuclear medicine
Published online: 2007-05-23
Submitted: 2012-01-23

Abstract

BACKGROUND: Ibritumomab is an 90Yttrium (90Y) labelled radioimmunoconjugate registered to treat follicular lymphoma relapsing or refractory after Rituximab therapy. Combining the specificity of anti CD20 monoclonal antibodies with the efficacy of radiotherapy, it is particularly effective in patients with advanced stages of disease with generalized lymphadenopathy.
MATERIAL AND METHODS: Twenty-one patients with follicular lymphoma, after failing 2-5 lines of previous treatment, were subjected to radioimmunotherapy in three Polish Lymphoma Research Group (PLRG) centres. Ibritumomab infusion was followed by 2 doses of Rituximab (250 mg/m2 at day -7 and 0) to enhance its biodistribution. Radioimmunoconjugate was prepared in the Nuclear Medicine Departments of participating centres based on patient weight and full blood count results (14.8 MBq/kg, max 1200 MBq, reduced to 11.1 MBq/kg in cases with blood platelet 100 000-150 000 or leukocytes 1500-2000).
14.8 MBq/kg (0.4 mCi/kg)
100 thousand to 149 thousand/mm3 platelets
11.1 MBq/kg (0.3 mCi/kg)
RESULTS: The primary endpoint of the study was the assessment of response rate and haematological toxicity. Objective responses were observed in all patients, with 10 partial and 12 complete regressions. Cytopenia, starting 3-4 weeks after radioimmunotherapy, reflected haematological toxicity - the only important side effect. Thrombocytopenia was more pronounced, with platelet counts of < 50,000/ul in every second patient. One patient developed myelodysplastic syndrome 21 months after the procedure. After the medium time of follow up over 2 years, 2 patients died. Median progression free survival (secondary study endpoint) was 15 months.
CONCLUSIONS: Ibritumomab radioimmunotherapy is an efficient method of palliation treatment of heavily pre-treated follicular lymphoma patients, failing numerous previous treatment lines. Earlier application increases the number of complete responses and prolongs progression free survival.

Abstract

BACKGROUND: Ibritumomab is an 90Yttrium (90Y) labelled radioimmunoconjugate registered to treat follicular lymphoma relapsing or refractory after Rituximab therapy. Combining the specificity of anti CD20 monoclonal antibodies with the efficacy of radiotherapy, it is particularly effective in patients with advanced stages of disease with generalized lymphadenopathy.
MATERIAL AND METHODS: Twenty-one patients with follicular lymphoma, after failing 2-5 lines of previous treatment, were subjected to radioimmunotherapy in three Polish Lymphoma Research Group (PLRG) centres. Ibritumomab infusion was followed by 2 doses of Rituximab (250 mg/m2 at day -7 and 0) to enhance its biodistribution. Radioimmunoconjugate was prepared in the Nuclear Medicine Departments of participating centres based on patient weight and full blood count results (14.8 MBq/kg, max 1200 MBq, reduced to 11.1 MBq/kg in cases with blood platelet 100 000-150 000 or leukocytes 1500-2000).
14.8 MBq/kg (0.4 mCi/kg)
100 thousand to 149 thousand/mm3 platelets
11.1 MBq/kg (0.3 mCi/kg)
RESULTS: The primary endpoint of the study was the assessment of response rate and haematological toxicity. Objective responses were observed in all patients, with 10 partial and 12 complete regressions. Cytopenia, starting 3-4 weeks after radioimmunotherapy, reflected haematological toxicity - the only important side effect. Thrombocytopenia was more pronounced, with platelet counts of < 50,000/ul in every second patient. One patient developed myelodysplastic syndrome 21 months after the procedure. After the medium time of follow up over 2 years, 2 patients died. Median progression free survival (secondary study endpoint) was 15 months.
CONCLUSIONS: Ibritumomab radioimmunotherapy is an efficient method of palliation treatment of heavily pre-treated follicular lymphoma patients, failing numerous previous treatment lines. Earlier application increases the number of complete responses and prolongs progression free survival.
Get Citation

Keywords

radioimmunotherapy; 90Y-ibritumomab tiuxetan (Zevalin); follicular lymphoma

About this article
Title

Radioimmunotherapy in follicular lymphomas, a retrospective analysis of the Polish Lymphoma Research Group’s (PLRG) experience

Journal

Nuclear Medicine Review

Issue

Vol 10, No 2 (2007)

Pages

91-97

Published online

2007-05-23

Bibliographic record

Nucl. Med. Rev 2007;10(2):91-97.

Keywords

radioimmunotherapy
90Y-ibritumomab tiuxetan (Zevalin)
follicular lymphoma

Authors

Wojciech Jurczak
Alicja Hubalewska-Dydejczyk
Agnieszka Giza
Anna Sowa-Staszczak
Tomasz Wróbel
Grzegorz Mazur
Piotr Boguradzki
Wanda Knopińska-Posłuszny
Bohdan Huszno
Aleksander B. Skotnicki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl